2022
DOI: 10.1093/eurheartj/ehac544.2959
|View full text |Cite
|
Sign up to set email alerts
|

Pathophysiological and therapeutic implications of urocortin-2 in heart failure with preserved ejection fraction

Abstract: Introduction Although initially believed to be less severe than heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF) prevalence has increased and accounts for as much as 50% of heart failure cases [1,2]. Treatment options remain limited and aim primarily for symptom relief and improvement of quality of life [2]. Urocortin-2 (Ucn-2) belongs to the corticotrophin-releasing hormone (CRH) family and has been found to have significant benefic… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles